This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Here's Why You Should Retain Cardinal Health (CAH) Stock Now
by Zacks Equity Research
Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and a diversified product portfolio. However, the cost of products continues to rise.
3 Reasons to Retain QIAGEN (QGEN) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about QIAGEN (QGEN) on the back of a series of product launches.
Here's Why You Should Retain Glaukos (GKOS) in Your Portfolio
by Zacks Equity Research
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
Alcon (ALC) Q3 Earnings Surpass Estimates, Sales Guidance Cut
by Zacks Equity Research
Alcon's (ALC) robust innovation pipeline is delivering solid results as evidenced by the strength in its comprehensive portfolio of PCIOLs, including PanOptix and Vivity.
Here's Why You Should Add McKesson (MCK) Stock Right Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.
The Zacks Analyst Blog Highlights Archer-Daniels-Midland, McKesson, Marathon Petroleum, Exxon Mobil and Merck & Co
by Zacks Equity Research
Archer-Daniels-Midland, McKesson, Marathon Petroleum, Exxon Mobil and Merck & Co are part of the Zacks top Analyst Blog.
PerkinElmer's (PKI) New Viral Vector Assays to Boost Workflows
by Zacks Equity Research
PerkinElmer's (PKI) latest launch is expected to help researchers expand options to measure viral titers, unlike ELISA and other wash-based systems.
5 Solid Dividend Growth Stocks for Thanksgiving
by Sweta Killa
Archer-Daniels-Midland (ADM), McKesson (MCK), ParkerHannifin (PH), Booz Allen Hamilton (BAH) and Darden Restaurants (DRI) could be compelling picks for your portfolio this Thanksgiving.
Is First Trust Consumer Staples AlphaDEX ETF (FXG) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FXG
Reasons to Retain AmerisourceBergen (ABC) in Your Portfolio
by Zacks Equity Research
AmerisourceBergen (ABC) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
Here's Why You Should Bet on ShockWave Medical (SWAV) Stock
by Zacks Equity Research
ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.
Medtronic (MDT) Q2 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
Medtronic's (MDT) Q2 organic revenues reflect slower supply recovery and lower-than-anticipated underlying market procedure volumes in certain businesses.
Here's Why You Should Hold on to Abiomed (ABMD) Stock Now
by Zacks Equity Research
Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.
Should Value Investors Buy McKesson (MCK) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Merit Medical's (MMSI) New Launch to Boost Patient Outcome
by Zacks Equity Research
Merit Medical's (MMSI) latest addition to its radial portfolio is expected to significantly optimize hemostasis for radial artery procedures.
Buy These 5 Corporate Giants Flying High in Disappointing 2022
by Nalak Das
We have narrowed our search to five U.S. corporate behemoths that have popped year to date. These are: ADM, MPC, XOM, MRK and MCK.
SmileDirectClub (SDC) Q3 Earnings Beat, Gross Margin Dips
by Zacks Equity Research
Challenges to consumer spending and sustained high inflation continue to impact SmileDirectClub's (SDC) overall expected demand for 2022.
Henry Schein's (HSIC) New Deal to Improve Patient Outcome
by Zacks Equity Research
Henry Schein's (HSIC) recent deal with Rimidi is expected to aid healthcare professionals in enhancing chronic disease management.
Should You Invest in the First Trust Consumer Staples AlphaDEX ETF (FXG)?
by Zacks Equity Research
Sector ETF report for FXG
Is SPDR Russell 1000 Momentum Focus ETF (ONEO) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for ONEO
What's in the Cards for Medtronic (MDT) in Q2 Earnings?
by Zacks Equity Research
Medtronic's (MDT) Evolut PRO+ launch in Europe and Evolut PRO launch in China are expected to have contributed to the company's fiscal Q3 top line.
Neogen's (NEOG) Synergize Disinfectant Now Widely Available
by Zacks Equity Research
Availability of Neogen's (NEOG) Synergize Disinfectant in other markets is expected to enhance global biosecurity portfolios, thereby safeguarding the food chain from harmful diseases.
Should SPDR Russell 1000 Momentum Focus ETF (ONEO) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for ONEO
NuVasive (NUVA) Q3 Earnings Beat Estimates, Guidance Cut
by Zacks Equity Research
The continued demand for NuVasive's (NUVA) Simplified Cervical Disc is encouraging.
Reasons to Add Merit Medical (MMSI) Stock to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Merit Medical (MMSI) owing to its strong product portfolio.